Designation of Lenalidomide (REVLIMID) as an orphan drug - Celgene Pty Ltd.

Overview

The Therapeutic Goods Act 1989, enacted by the Parliament of Australia, serves to regulate the supply of therapeutic goods within the country, aiming to ensure their safety, quality, and efficacy. One of the legislative mechanisms within this Act is the designation of orphan drugs, which addresses the problem of limited incentives for the development of treatments for rare diseases due to the relatively small patient population. This designation aims to encourage the research, development, and availability of such treatments by providing certain benefits and incentives to sponsors. The Delegate of the Secretary for the purposes of 16J of the Therapeutic Goods Regulations 1990, Dr Anthony Gill, designated Lenalidomide (REVLIMID) as an orphan drug on 28 January 2015 for the treatment of patients with mantle cell lymphoma, highlighting the policy objective of enhancing access to necessary treatments for rare diseases.

Scope and Application

The Therapeutic Goods Act 1989, administered by the Therapeutic Goods Administration (TGA) within the Australian Department of Health, encompasses the regulation and control of therapeutic goods in Australia. Specifically, this Act applies to the designation of certain therapeutic substances, such as drugs, for particular medical conditions that meet the criteria for orphan drugs. This legislative action is designed to encourage the research, development and availability of treatments for rare diseases or conditions that otherwise might not attract commercial interest due to their limited prevalence. In this instance, Lenalidomide (REVLIMID) has been designated as an orphan drug for the treatment of mantle cell lymphoma, a rare form of blood cancer. This designation applies to the specific pharmaceutical form of the drug, namely capsules, as indicated by the sponsor, Celgene Pty Ltd. The Act’s reach is nationwide, extending across all jurisdictions within Australia, ensuring a unified approach to the regulation of therapeutic goods. Notably, the designation of an orphan drug under the Act does not exempt the drug from other regulatory requirements but rather provides specific incentives and support for its development and availability. The Therapeutic Goods Act 1989 allows for the extension and refinement of its application through subordinate instruments, such as the Therapeutic Goods Regulations 1990. These regulations support the overarching principles of the Act by providing detailed guidance on processes such as the designation of orphan drugs. The Delegate of the Secretary, Dr. Anthony Gill, exercised authority under subregulation 16J(2) to designate Lenalidomide (REVLIMID) as an orphan drug, thereby facilitating access to this treatment for patients with mantle cell lymphoma. While the Act itself sets out the general framework and objectives, the regulations offer the necessary mechanisms to operationalise these objectives. There are no exclusions or exemptions explicitly stated in the provided text, but it is understood that the designation process is subject to the overall regulatory oversight and compliance requirements under the Therapeutic Goods Act 1989 and its associated regulations.

Key Provisions

The main operative sections of the Therapeutic Goods Act 1989, as referenced in the designation of Lenalidomide (REVLIMID) as an orphan drug, involve the use of subregulation 16J(2) of the Therapeutic Goods Regulations 1990. This subregulation allows for the designation of certain therapeutic goods as orphan drugs when they are intended for use in rare conditions. In this instance, Lenalidomide (REVLIMID) has been designated for the treatment of patients with mantle cell lymphoma, a rare form of non-Hodgkin lymphoma. The designation (section 16J(2)) is made by Dr. Anthony Gill, acting as the Delegate of the Secretary, and specifies the therapeutic use and the form of the drug (section 41AD(1)). This designation is crucial as it acknowledges the rarity of the condition and aims to encourage the development of treatments for such diseases. The obligations imposed by this designation on the parties involved, particularly the sponsor, Celgene Pty Ltd, include ensuring that the drug meets the required standards for safety and efficacy as stipulated by the Therapeutic Goods Administration (TGA). The sponsor must also provide all necessary information and data required by the TGA to support the orphan drug designation. Furthermore, the sponsor is required to comply with any additional requirements or conditions imposed by the TGA as part of the drug approval process. This includes submitting clinical trial data, manufacturing information, and other relevant documentation that ensures the therapeutic good is safe and effective for its intended use. In the event of non-compliance or breach of the requirements stipulated under the Therapeutic Goods Act 1989 and the Therapeutic Goods Regulations 1990, various penalties and consequences may apply. For example, any person who contravenes the provisions of the Act, such as by manufacturing, supplying, or advertising a therapeutic good that does not comply with the regulations, may be subject to civil or criminal penalties. Under the Act, the maximum penalty for a corporation found guilty of such an offence can include fines up to a significant amount, as specified by the legislation. Additionally, individuals involved in the breach may face personal fines and, in severe cases, imprisonment. These provisions ensure that the integrity and safety of therapeutic goods in Australia are upheld, protecting public health.